$CTRV (ContraVir Pharmaceuticals, Inc.)

$CTRV {{ '2016-09-22T12:10:21+0000' | timeago}} • Announcement

Biopharmaceutical company $CTRV has appointed Thomas H. Adams to its BoD. Dr. Adams currently serves as Chairman of the Board for Trovagene, Inc. He is also a director of Synergy Pharmaceuticals, Inc. He has previously worked with IRIS International, Inc. and Leucadia Technologies.

$XPER {{ '2017-07-05T13:11:54+0000' | timeago}} • Announcement

$XPER business Tessera Technologies said the US International Trade Commission has issued a favorable order on the company’s patent infringement dispute with $BRCM. Tessera’s counsel has confirmed the broad scope of the company’s victory in the lawsuit, related mainly to infringement of patents of semiconductor chips.

$AOBC {{ '2017-06-30T13:55:31+0000' | timeago}} • Webcast

$AOBC said its internal inventory levels were slightly elevated in 4Q17, mainly in firearms, and the Smith & Wesson maker expects those levels to continue rising over the next several months building inventory for the fall hunting and holiday season.

$AOBC {{ '2017-06-30T13:44:51+0000' | timeago}} • Webcast

As $AOBC posted 4Q17 results, the company said, "we expect the seasonal impact on our revenue to be much more pronounced in the first-half of fiscal 2018"

$AOBC {{ '2017-06-30T13:37:56+0000' | timeago}} • Webcast

Regarding $AOBC's 500,000-square foot distribution center in Missouri, construction expected to take at least 18 months and the entire project requiring two to three years to complete, the company announced as it posted 4Q17 results.

$AOBC {{ '2017-06-29T20:34:15+0000' | timeago}} • Infographic

$AOBC American Outdoor Brands Corporation Earnings AlphaGraphic: Q4 2017 Highlights

$AOBC {{ '2017-06-29T20:28:56+0000' | timeago}} • Announcement

In FY18, $AOBC expects to continue employing strength of its balance sheet, including unused portion of its revolving line of credit, which is expandable up to $500MM, to fuel additional growth opportunities, both organic and inorganic.

$AOBC {{ '2017-06-29T20:27:11+0000' | timeago}} • Announcement

$AOBC expects 1Q18 net sales of $140-150MM, EPS of $0.01-0.06 and non-GAAP EPS of $0.07-0.12. For the full year 2018, the company predicts net sales of $750-790MM, EPS of $1.16-1.36 and non-GAAP EPS of $1.42-1.62.

$AOBC {{ '2017-06-29T20:25:15+0000' | timeago}} • Announcement

$AOBC reported a drop in 4Q17 earnings due to higher costs and expenses. Net income fell to $27.69MM or $0.50 per share from $35.65MM or $0.63 per share last year. Net sales grew to $229.19MM from $221.12MM, on growth in its Firearms and Outdoor products and accessories segments. Non-GAAP EPS decreased to $0.57 from $0.66.

$BIVV {{ '2017-06-28T20:37:42+0000' | timeago}} • Announcement

$BIVV successfully closed its acquisition of True North Therapeutics, a privately-held, clinical-stage rare disease biotechnology company. The acquisition advances $BIVV's vision of becoming the leading rare disease company focused on blood disorders.

$FTI {{ '2017-06-13T21:48:54+0000' | timeago}} • Announcement

$FTI received an extension to its ongoing Engineering, Procurement and Construction (EPC) contract from Statoil in the Norwegian North Sea. The project will be executed as an integrated Engineering, Procurement, Construction and Installation (iEPCI).

$BIVV {{ '2017-06-12T14:42:33+0000' | timeago}} • Announcement

Biotech firm $BIVV said the FDA has accepted its investigational new drug application for BIVV001, a novel therapy for extending protection from bleeds in people with hemophilia A. BIVV001 is the only investigational factor-VIII therapy in development that is designed to overcome the von Willebrand factor ceiling.

$HOME {{ '2017-06-07T13:56:02+0000' | timeago}} • Infographic

$HOME At Home Group Inc. Earnings AlphaGraphic: Q1 2018 Highlights

$FTI {{ '2017-06-07T13:30:07+0000' | timeago}} • Announcement

$FTI entered into a 3-year frame agreement with Woodside Energy Ltd in Australia for Riserless Light Well Intervention (RLWI) and subsea services. $FTI will install subsea trees and deploy its deepwater RLWI stack to perform well intervention services on up to eight subsea wells in the GWF-2 development.

$HOME {{ '2017-06-07T12:24:03+0000' | timeago}} • Announcement

$HOME has raised its sales outlook for fiscal 2018 to the range of $906-913MM, representing a 18-19% growth. Comparable store sales are seen increasing around 3%. Net profit is forecasted to be $39.4-41.0MM, and EPS between $0.62 and $0.64. $HOME increased the midpoint of its adjusted EPS and now the EPS is expected at $0.73-0.75.

$HOME {{ '2017-06-07T12:08:08+0000' | timeago}} • Announcement

Retail chain $HOME reported a 37% annual growth in 1Q18 profit to $10MM, due to higher sales. Earnings per share rose to $0.16 from $0.14 last year. On an adjusted basis, profit and EPS increased 32% and 27% YoY respectively. Net sales surged 23% to $211.84MM, helped by the addition of 23 new stores and a 5.8% gain in comparable store sales.

$XPER {{ '2017-06-02T13:40:02+0000' | timeago}} • Announcement

Invensas Corp., a subsidiary of $XPER, said a German appellate court denied $AVGO and Broadcom Corp.'s motion to stay enforcement of a patent infringement judgment that a German district court recently entered against Broadcom.

$FTI {{ '2017-06-02T11:24:09+0000' | timeago}} • Announcement

$FTI, together with JGC Corporation and Samsung Heavy Industries, all partners in the TJS Consortium, has been awarded by CORAL FLNG SA a major contract. It covers EPCIC of the Coral South FLNG facility and its associated risers and subsea flowlines system, as well as the installation of the umbilicals and subsea equipment by offshore Mozambique.

$BIVV {{ '2017-05-23T13:22:32+0000' | timeago}} • Announcement

$BIVV agreed to buy True North Therapeutics. The acquisition will be financed through a combination of cash on hand and debt. The acquisition is expected to close in mid-2017.

$BIVV {{ '2017-05-23T13:20:59+0000' | timeago}} • Announcement

$BIVV said it will obtain worldwide rights to True North's lead candidate, TNT009, a first-in-class monoclonal antibody in development to treat cold agglutinin disease (CAD). CAD is a rare and chronic hemolytic condition that often leads to severe anemia, requiring numerous transfusions, and can result in life-threatening thrombotic events.

$BIVV {{ '2017-05-23T13:18:48+0000' | timeago}} • Announcement

$BIVV agreed to buy South San Francisco-based privately-held True North Therapeutics, a clinical-stage rare disease biotechnology company, for upfront of $400MM plus assumed cash. True North investors are also eligible to get additional payments of up to $425MM contingent on achievement of future development, regulatory and sales milestones.

Recent Transcripts

CPAC (Cementos Pacasmayo SAA)
Friday, July 21 2017 - 4:30pm
MNI (The McClatchy Company)
Friday, July 21 2017 - 4:00pm
MINI (Mobile Mini, Inc.)
Friday, July 21 2017 - 4:00pm
WAL (Western Alliance Bancorporation)
Friday, July 21 2017 - 4:00pm
ASR (Grupo Aeroportuario del Sureste, SAB de CV)
Friday, July 21 2017 - 3:30pm
MCO (Moody's Corporation)
Friday, July 21 2017 - 3:30pm
CARO (Carolina Financial Corporation)
Friday, July 21 2017 - 3:01pm
MBFI (MB Financial Inc.)
Friday, July 21 2017 - 3:00pm
SXT (Sensient Technologies Corporation)
Friday, July 21 2017 - 3:00pm
GBCI (Glacier Bancorp, Inc.)
Friday, July 21 2017 - 3:00pm
NBHC (National Bank Holdings Corp.)
Friday, July 21 2017 - 3:00pm
SBFG (SB Financial Group, Inc.)
Friday, July 21 2017 - 3:00pm
CL (Colgate-Palmolive Co.)
Friday, July 21 2017 - 3:00pm
BLX (Banco Latinoamericano de Comercio Exterior, S.A)
Friday, July 21 2017 - 3:00pm
RF (Regions Financial Corporation)
Friday, July 21 2017 - 3:00pm
COBZ (CoBiz Financial Inc.)
Friday, July 21 2017 - 3:00pm
BMI (Badger Meter Inc.)
Friday, July 21 2017 - 3:00pm
EQBK (Equity Bancshares, Inc.)
Friday, July 21 2017 - 2:00pm
QCRH (QCR Holdings Inc.)
Friday, July 21 2017 - 2:00pm
INDB (Independent Bank Corp.)
Friday, July 21 2017 - 2:00pm

AlphaGraphics you may like